TD-AY286014

ELISA

Rabbit

IgG

Polyclonal

Trastuzumab

Rabbit polyclonal to Herceptin.

The product is specific for Trastuzumab. This antibody serves as an excellent positive control for Trastuzumab immunogenicity (ADA) assays.

Please contact with the lab for this information.

Purified by antigen affinity column.

CAS: 180288-69-1

Liquid

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

ELISA　|　IHC　|　WB

1:5000-1:20000　|　1:50-1:500　|　1:500-1:2000

The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.

Trastuzumab with the brand name Herceptin, is an FDA-approved drug for HER2-targeted therapy for breast cancer. It is a recombinant humanized monoclonal antibody (IgG1 kappa). Trastuzumab binds to HER2 receptor present on the surface of HER2-positive tumour cells and suppresses the cells growth and proliferation.• Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro., PMID:28919583• Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies., PMID:19393584• Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines., PMID:32102522• Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells., PMID:16091755• Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3)., PMID:19530101• Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity., PMID:12632061• IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831., PMID:28533226• Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer., PMID:11410505• Immunohistochemical detection of Her-2/neu overexpression in breast carcinoma in Nigerians: a 5-year retrospective study., PMID:22037080• Polyclonal antitumor immunoglobulin may play a role in ovarian cancer adjuvant therapy., PMID:21255939

For research use only.